Paeoniflorin Modulates Tmem176b+ Macrophage Polarization in Hepatic Ischemia-Reperfusion Injury

Study Background and Research Question

Hepatic ischemia-reperfusion (I/R) injury is a significant clinical complication arising during liver transplantation and extensive hepatic resections, contributing to early allograft dysfunction and limiting graft survival. Despite advances in surgical technique and perioperative care, the fundamental mechanisms underlying hepatic I/R injury remain incompletely understood, and effective interventions are scarce. Macrophages, particularly their polarization states, are central mediators of the hepatic inflammatory response to I/R. The switch between pro-inflammatory (M1) and reparative (M2) macrophage phenotypes shapes the balance between tissue damage and recovery. Paeoniflorin (PF), a bioactive glycoside from Paeonia species, is known for its hepatoprotective and immunomodulatory properties, but its precise impact on macrophage dynamics in hepatic I/R contexts had not been fully elucidated prior to this study. The central aim was to determine whether and how PF modulates macrophage polarization, with a particular focus on Tmem176b+ macrophages, during liver I/R injury (reference study).

Key Innovation from the Reference Study

The primary innovation of this work lies in the integration of single-cell RNA sequencing (scRNA-seq) to resolve macrophage heterogeneity and dynamic phenotypic shifts in a PF-treated hepatic I/R mouse model. The study identifies a previously underappreciated therapeutic axis: PF facilitates a functional transition of Tmem176b+ macrophages from an M1-like, pro-inflammatory state toward an M2-like, reparative phenotype. This polarization shift is shown to be both necessary and sufficient for the observed hepatoprotective effects, with Tmem176b+ macrophages acting as critical effectors. Mechanistically, the study uncovers dual regulation of immune signaling pathways by PF: upregulation of the immunosuppressive THBS1-CD47 axis and suppression of the pro-inflammatory SPP1-CD44 pathway in Tmem176b+ macrophages.

Methods and Experimental Design Insights

The experimental approach was centered on a murine model of hepatic I/R injury, comprising controlled hepatic blood flow occlusion and reperfusion, followed by treatment with paeoniflorin. High-resolution scRNA-seq was performed on 45,673 isolated liver cells to dissect cell-type-specific transcriptional responses. Bioinformatic analyses included clustering, pseudotime trajectory mapping, and ligand-receptor interactome modeling to elucidate macrophage subset dynamics and cell-cell communication shifts. Functional validation was achieved through pharmacological inhibition of Tmem176b and in vivo depletion of macrophages using liposome-encapsulated clodronate. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, histopathological scoring, and apoptosis markers were used to assess hepatic injury and recovery.

Protocol Parameters

• Hepatic I/R model induction: Clamp hepatic inflow for a defined period (typically 60 min), followed by reperfusion; adjust based on mouse strain and experimental question.
• Paeoniflorin administration: Dose and timing should align with preclinical tolerability and pharmacokinetics (e.g., 30–50 mg/kg intraperitoneally prior to reperfusion, as commonly reported in literature).
• Macrophage depletion: Liposome-encapsulated clodronate is administered intravenously (e.g., 100–200 µL per mouse) 24–48 h before I/R induction to ensure effective depletion; refer to specific product protocol and adjust for animal weight.
• Single-cell RNA sequencing: Immediate liver tissue dissociation and single-cell isolation post-reperfusion; library preparation protocols should preserve cell surface markers and viability.

Core Findings and Why They Matter

PF treatment led to marked improvement in hepatic function, as evidenced by reduced serum ALT/AST levels and diminished necrosis and apoptosis in the liver. scRNA-seq revealed that PF preferentially recalibrates macrophage subpopulations, notably driving Tmem176b+ macrophages toward an M2-like, anti-inflammatory phenotype. Pseudotime analysis demonstrated a clear trajectory of inflammatory macrophages transitioning into this reparative state under PF influence. Importantly, targeted depletion of Tmem176b+ macrophages or inhibition of Tmem176b signaling abrogated PF's hepatoprotective effects, establishing these cells as indispensable mediators. Mechanistically, PF upregulated THBS1-CD47 interactions—linked to immune suppression and tissue repair—while suppressing SPP1-CD44 signaling, a known driver of inflammation and fibrosis. These findings underscore a dual immunometabolic checkpoint governing macrophage function in liver I/R, with potential for therapeutic exploitation (see study details).

Comparison with Existing Internal Articles

The present study’s use of in vivo macrophage depletion via liposome-encapsulated clodronate closely parallels approaches discussed in several internal reviews. For instance, "Clodronate Liposomes: Dissecting Macrophage Polarization in Liver Injury Models" emphasizes how selective macrophage removal unravels polarization dynamics and the interplay between immune cell subsets during hepatic injury. Similarly, "Clodronate Liposomes: Precision Tools for Functional Macrophage Studies" highlights the utility of apoptosis induction in macrophages for mechanistic dissection and immune cell modulation. The present research extends these insights by focusing on a specific macrophage subpopulation (Tmem176b+) and mapping the downstream signaling alterations underpinning PF’s effects, thus advancing the mechanistic granularity of in vivo macrophage depletion workflows.

Limitations and Transferability

While the study leverages robust single-cell technologies and functional in vivo assays, several limitations warrant consideration. The findings are derived from murine models; species differences in macrophage subtypes and polarization responses may impact translational relevance to human transplantation. The scRNA-seq approach, while granular, is limited by tissue dissociation artifacts and snapshot sampling. Moreover, the functional depletion strategy, though effective, can also impact other phagocytic cells, potentially confounding the attribution of effects solely to Tmem176b+ macrophages. Finally, the precise upstream triggers for PF’s modulation of the THBS1-CD47 and SPP1-CD44 axes require further clarification in diverse injury contexts.

Research Support Resources

Researchers aiming to dissect macrophage function in hepatic or other tissue injury models can utilize Clodronate Liposomes (SKU K2721) for selective in vivo macrophage depletion. This reagent streamlines phagocytosis-mediated drug delivery and apoptosis induction in macrophages, with established compatibility for multiple administration routes and animal models. For experimental controls, PBS Liposomes are recommended. Protocols should be tailored to the experimental system and research goals; detailed guidance is available in the product information.